Iantrek

Website

Iantrek, Inc.

4 Investors
Medical Technology
WHITE PLAINS, NY

Iantrek, Inc. is a pioneering medical technology company dedicated to enhancing glaucoma treatment through innovative solutions tailored for micro-interventional glaucoma surgery (MIGS). With a focus on addressing the pressing global challenge of glaucoma, a leading cause of irreversible blindness affecting over 75 million people worldwide, Iantrek is committed to improving patient outcomes and surgical precision in eye care.

Products & Team

CycloPen System

Medical DeviceSeed

The CycloPen System is a micro-interventional device designed specifically for ophthalmologists. It facilitates the controlled creation or modification of cyclodialysis, effectively targeting the suprachoroidal outflow pathway, thereby enhancing surgical outcomes for glaucoma patients.

Value Proposition

The CycloPen System addresses the challenge of managing intraocular pressure in glaucoma patients by providing a minimally invasive intervention option to enhance aqueous humor outflow.

Pain Points

These specialists face challenges in providing effective glaucoma treatment while minimizing invasive procedures and reducing the need for patient reliance on medication.

Micro-interventional designControlled creation/modification of cyclodialysisTargets suprachoroidal outflow pathway
Industry
Biotechnology
Primary business sector
Founded
2025
Year established
Location
WHITE PLAINS, NY
Primary headquarters

Funding History

Total Raised:
$2.8M
E

Debt Financing, Option to Acquire Offering

February 2025
$5.5M
Target
Use of Proceeds
No amounts other than ordinary course employment compensation is being paid to officers and directors.
Progress
51%
Raised
$2.8M
Target
$5.5M
#000182998225000001